Ionis Pharmaceuticals Inc (NASDAQ: IONS) has benefited from exceptional positive changes in investment behavior: its shorter term price trend turned up, its longer term price trend turned up, the stock’s recent price rise disrupted its longer term downtrend, and the stock rose on very heavy volume.
In light of these very positive signals we are reviewing our current Overall Rating of F. We would view the shares with optimism pending completion of this review in the next several days.
Current PriceTarget Research Rating
IONS is expected to continue to be a modest Value Builder reflecting capital returns that are forecasted to be above the cost of capital.
Ionis Pharmaceuticals has a current Value Trend Rating of F (Lowest Rating). The Value Trend Rating reflects consistent signals from PTR’s two proprietary measures of a stock’s attractiveness. Ionis Pharmaceuticals has a poor Power Rating of 22 and a very low Appreciation Score of 3, producing the Lowest Value Trend Rating.
Recent Price Action
On 6/26/24, Ionis Pharmaceuticals Inc (NASDAQ: IONS) stock increased 1.5%, closing at $47.70. Moreover, trading volume in this advance was exceptionally high at 209% of normal. The stock has been extremely weak relative to the market over the last nine months but has risen 17.0% during the last week.
Be the first to comment